Skip to content
OpenCapital
Get started

LivaNova LIVN Cardiopulmonary — R&D

Other segment segments

Neuromodulation
$40.79M+59.5%

Similar metrics at other companies

Medtronic logo
MDTCardiovascular — Research and development expense
$273M+5.4%
Boston Scientific logo
BSXCardiovascular — Research and development expenses
$343M+21.2%
Boston Scientific logo
BSXCardiovascular — Research and development expenses, percentage of net sale
9.8%+0.8pp
Becton, Dickinson and Company logo
BDXConnected Care — Research and development expense
$90M+21.6%
Penumbra logo
PENR&D
$22.38M+1.4%
Abbott logo
ABTDiagnostic Products — R&D
$155M+2.6%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's cardiopulmonary — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's cardiopulmonary — R&D?
LivaNova (LIVN) reported cardiopulmonary — R&D of $17.8M in Q1 2026.
How has LivaNova's cardiopulmonary — R&D changed year-over-year?
LivaNova's cardiopulmonary — R&D increased by 47.7% year-over-year, from $12.04M to $17.8M.
What is the long-term trend for LivaNova's cardiopulmonary — R&D?
Over 3 years (2022 to 2025), LivaNova's cardiopulmonary — R&D has grown at a 16.0% compound annual growth rate (CAGR), from $42.11M to $65.74M.
What does cardiopulmonary — R&D mean?
Reflects the expenditures dedicated to innovation, product development, and clinical trials within the cardiopulmonary segment. This metric is a key indicator of the company's commitment to long-term growth and maintaining a competitive technological edge.